

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51104034>

# Contributions of the D-Ring to the Activity of Etoposide against Human Topoisomerase II $\alpha$ : Potential Interactions with DNA in the Ternary Enzyme–Drug–DNA Complex

ARTICLE *in* BIOCHEMISTRY · JUNE 2011

Impact Factor: 3.02 · DOI: 10.1021/bi200531q · Source: PubMed

---

CITATIONS

13

---

READS

9

9 AUTHORS, INCLUDING:



[Daniel Dauzonne](#)

Institut Curie

106 PUBLICATIONS 1,112 CITATIONS

SEE PROFILE



[Claude Monneret](#)

Institut Curie

278 PUBLICATIONS 3,239 CITATIONS

SEE PROFILE



[David E Graves](#)

University of Alabama at Birmingham

85 PUBLICATIONS 1,811 CITATIONS

SEE PROFILE

# Contributions of the D-Ring to the Activity of Etoposide against Human Topoisomerase II $\alpha$ : Potential Interactions with DNA in the Ternary Enzyme–Drug–DNA Complex

Steven L. Pitts,<sup>†</sup> Michael J. Jablonksy,<sup>§</sup> Maria Duca,<sup>||,▽</sup> Daniel Dauzonne,<sup>⊥,@</sup> Claude Monneret,<sup>⊥,@</sup> Paola B. Arimondo,<sup>||,●</sup> Clemens Anklin,<sup>#</sup> David E. Graves,<sup>\*,§</sup> and Neil Osheroff<sup>†,\*,†,‡</sup>

<sup>†</sup>Department of Biochemistry and <sup>‡</sup>Department of Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States

<sup>§</sup>Department of Chemistry, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States


<sup>||</sup>UMR7196 CNRS, Muséum National d'Histoire Naturelle, INSERM UR565, 75005 Paris, France

<sup>⊥</sup>Centre de Recherche, Institut Curie, 75248 Paris, France

<sup>@</sup>Institut Curie Section de Recherche, UMR176 CNRS, 75248 Paris, France

<sup>#</sup>Bruker BioSpin Corporation, Billerica, Massachusetts 01821, United States

**ABSTRACT:** Etoposide is a widely prescribed anticancer drug that stabilizes covalent topoisomerase II-cleaved DNA complexes. The drug contains a polycyclic ring system (rings A–D), a glycosidic moiety at C4, and a pendant ring (E-ring) at C1. Interactions between human topoisomerase II $\alpha$  and etoposide in the binary enzyme–drug complex appear to be mediated by substituents on the A-, B-, and E-rings of etoposide. These protein–drug contacts in the binary complex have predictive value for the actions of etoposide within the ternary topoisomerase II $\alpha$ –drug–DNA complex. Although the D-ring of etoposide does not appear to contact topoisomerase II $\alpha$  in the binary complex, etoposide derivatives with modified D-rings display reduced cytotoxicity against murine leukemia cells [Meresse, P., et al. (2003) *Bioorg. Med. Chem. Lett.* 13, 4107]. This finding suggests that alterations in the D-ring may affect etoposide activity toward topoisomerase II $\alpha$  in the ternary enzyme–drug–DNA complex. Therefore, to address the potential contributions of the D-ring to the activity of etoposide, we characterized drug derivatives in which the C13 carbonyl was moved to the C11 position (retroetoposide and retroDEPT) or the D-ring was opened (D-ring diol). All of the D-ring alterations decreased the ability of etoposide to enhance DNA cleavage mediated by human topoisomerase II $\alpha$  in vitro and in cultured cells. They also weakened etoposide binding in the ternary enzyme–drug–DNA complex and altered sites of enzyme-mediated DNA cleavage. On the basis of these findings, we propose that the D-ring of etoposide has important interactions with DNA in the ternary topoisomerase II cleavage complex.



Etoposide is a highly successful anticancer agent that has been used to treat a variety of blood-borne and solid human malignancies for nearly 30 years.<sup>1–4</sup> The drug is a derivative of podophyllotoxin, a naturally occurring antimitotic agent from May apples.<sup>1,5</sup> Etoposide kills cells by stabilizing covalent topoisomerase II-cleaved DNA complexes that are formed during the DNA strand passage reaction of the enzyme.<sup>6–9</sup> These transient “cleavage complexes” are converted to permanent DNA strand breaks by collisions with DNA tracking systems, which generate chromosomal aberrations, destabilize the genome, and trigger cell death pathways.<sup>7–12</sup> Because etoposide converts topoisomerase II to a cellular toxin, it is termed a topoisomerase II poison.<sup>6–9</sup>


Humans encode two closely related isoforms of topoisomerase II, topoisomerase II $\alpha$  and topoisomerase II $\beta$ .<sup>13–16</sup> The individual contributions of these isoforms to the clinical efficacy of etoposide have yet to be determined. However, recent evidence suggests that topoisomerase II $\alpha$  may play a more

prominent role in mediating the cytotoxic effects of topoisomerase II-targeted anticancer drugs.<sup>17–19</sup> Coupled with the fact that the concentration of topoisomerase II $\alpha$  is generally higher in malignant than in corresponding normal tissues, most studies of etoposide action have focused on the  $\alpha$  isoform.<sup>20–22</sup>

Previous studies indicate that interactions between topoisomerase II and etoposide are critical for drug activity and mediate the entry of etoposide into the ternary enzyme–drug–DNA complex.<sup>23–26</sup> Therefore, substituents on etoposide that contact topoisomerase II in the binary enzyme–drug complex have been identified by STD <sup>1</sup>H NMR spectroscopy.<sup>25,26</sup> These substituents include the C15 geminal protons of the A-ring, the C5 and C8 protons of the B-ring, the C2' and C6' protons of the pendant E-ring, and the 3'- and

**Received:** April 8, 2011

**Published:** May 06, 2011



**Figure 1.** Structures of etoposide, retroetoposide, DEPT, retroDEPT, and the D-ring diol.

5'-methoxy protons of the E-ring (Figure 1). In contrast, no protein contacts have been observed for the C1 and C4 protons of the C-ring, the C2 and C3 protons that bridge the C- and D-rings, the C11 protons of the D-ring, or any protons on the C4 glycosidic moiety. An identical set of drug contacts was seen in a binary complex of topoisomerase II $\alpha$  and DEPT, an etoposide derivative that lacks the C4 glycosidic group (Figure 1).

Protein–drug contacts in the binary complex have predictive value for the actions of etoposide within the ternary topoisomerase II–drug–DNA complex.<sup>25,26</sup> Opening of the A-ring or altering the 3', 4', or 5' substituents of the E-ring dramatically decreases the efficacy of etoposide but does not affect the specificity of DNA cleavage.<sup>25,26</sup> Thus, it was concluded that etoposide interacts with topoisomerase II through the A-, B-, and E-rings. Conversely, the loss of the C4 glycosidic group in DEPT has relatively little effect on the ability of the drug to enhance topoisomerase II-mediated DNA scission but does induce subtle changes in cleavage specificity and site utilization.<sup>26</sup> Consequently, it has been suggested that the C4 glycoside, along with the D-ring, may mediate interactions with DNA in the cleavage complex.<sup>26</sup>

Therefore, to explore potential interactions between the D-ring and DNA during topoisomerase II-mediated DNA cleavage, we characterized a series of etoposide derivatives, including retroetoposide, retroDEPT, and the D-ring diol. Results indicate that D-ring alterations decrease the ability of etoposide to enhance DNA cleavage mediated by human topoisomerase II $\alpha$  in vitro and in cultured human cells. They also weaken etoposide binding in the ternary enzyme–drug–DNA complex and alter

sites of enzyme-mediated DNA cleavage. On the basis of these findings, we conclude that the D-ring of etoposide has important interactions with DNA in the topoisomerase II cleavage complex.

## EXPERIMENTAL PROCEDURES

**Materials.** Human topoisomerase II $\alpha$  was expressed in *Saccharomyces cerevisiae* and purified as described previously.<sup>27,28</sup> However, in the final step of the purification, topoisomerase II $\alpha$  was eluted from the phosphocellulose column (P81, Whatman) with buffer containing 10 mM sodium phosphate (pH 7.7), 750 mM KCl, 1 mM EDTA, 1 mM EGTA, and 0.5 mM dithiothreitol. For protein samples that were used in NMR experiments, the elution buffer was made up in D<sub>2</sub>O (99.9%, Aldrich) instead of H<sub>2</sub>O. Negatively supercoiled pBR322 plasmid DNA was prepared using a Plasmid Mega Kit (Qiagen) as described by the manufacturer. Etoposide was purchased from Sigma. Retroetoposide, DEPT, retroDEPT, and the D-ring diol were synthesized as described previously.<sup>29</sup> All drugs were stored at 4 °C as 20 mM stock solutions in 100% DMSO. Drugs used for NMR experiments were stored in 100% *d*-DMSO. All other chemicals were analytical reagent grade.

**Cleavage of Plasmid DNA by Human Topoisomerase II $\alpha$ .** DNA cleavage reactions were carried out using the procedure of Fortune and Osheroff.<sup>30</sup> Unless stated otherwise, assay mixtures contained 150 nM topoisomerase II $\alpha$  and 10 nM negatively supercoiled pBR322 DNA in a total of 20  $\mu$ L of cleavage buffer [10 mM Tris-HCl (pH 7.9), 100 mM KCl, 5 mM MgCl<sub>2</sub>, 0.1 mM NaEDTA, and 2.5% glycerol] that contained 0–200  $\mu$ M

etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol. DNA cleavage was initiated by the addition of enzyme, and mixtures were incubated for 6 min at 37 °C to establish DNA cleavage–ligation equilibria. Enzyme–DNA cleavage intermediates were trapped by adding 2  $\mu$ L of 5% SDS and 1  $\mu$ L of 375 mM EDTA (pH 8.0). Proteinase K was added (2  $\mu$ L of a 0.8 mg/mL solution), and reaction mixtures were incubated for 30 min at 45 °C to digest the topoisomerase II $\alpha$ . Samples were mixed with 2  $\mu$ L of 60% sucrose in 10 mM Tris-HCl (pH 7.9), 0.5% bromophenol blue, and 0.5% xylene cyanol FF, heated for 15 min at 45 °C, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA that contained 0.5  $\mu$ g/mL ethidium bromide. DNA cleavage was monitored by the conversion of negatively supercoiled plasmids to linear molecules. DNA bands were visualized by ultraviolet light and quantified using an Alpha Innotech digital imaging system.

**DNA Ligation.** DNA ligation mediated by topoisomerase II $\alpha$  was monitored according to the procedure of Byl et al.<sup>31</sup> Topoisomerase II $\alpha$  DNA cleavage–ligation equilibria were established as described above in the absence of compound or in the presence of 100  $\mu$ M etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol. Ligation was initiated by cooling reaction mixtures from 37 to 0 °C, and reactions were stopped at time points up to 30 s by the addition of 2  $\mu$ L of 5% SDS followed by 1  $\mu$ L of 375 mM NaEDTA (pH 8.0). Samples were processed and analyzed as described above for plasmid DNA cleavage reactions.

**Drug-Induced DNA Cleavage Mediated by Topoisomerase II $\alpha$  in Cultured Human CEM Cells.** Human CEM acute lymphoblastic leukemia cells (ATCC) were cultured under 5% CO<sub>2</sub> at 37 °C in RPMI 1640 medium (Cellgro by Mediatech, Inc.) containing 10% heat-inactivated fetal calf serum (Hyclone) and 2 mM glutamine (Cellgro by Mediatech, Inc.). The *In vivo* Complex of Enzyme (ICE) bioassay<sup>32,33</sup> (as modified on the TopoGEN, Inc., website) was employed to determine the ability of 25  $\mu$ M etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol to induce topoisomerase II $\alpha$ -mediated DNA breaks in CEM cells. Exponentially growing cultures were treated with DMSO or drugs for 1 h. Cells ( $\sim 5 \times 10^6$ ) were harvested by centrifugation and lysed by the immediate addition of 3 mL of 1% sarkosyl. Following gentle dounce homogenization, cell lysates were layered onto a 2 mL cushion of CsCl (1.5 g/mL) and centrifuged in a Beckman NVT 90 rotor at 80000 rpm ( $\sim 500000g$ ) for 5.5 h at 20 °C. DNA pellets were isolated, resuspended in 5 mM Tris-HCl (pH 8.0) and 0.5 mM EDTA, and blotted onto nitrocellulose membranes using a Schleicher and Schuell slot blot apparatus. Covalent cleavage complexes formed between topoisomerase II $\alpha$  and chromosomal DNA were detected using a polyclonal antibody directed against human topoisomerase II $\alpha$  (Kiamaya Biochemical Co.) at a 1:1000 dilution.


**STD <sup>1</sup>H NMR Spectroscopy.** NMR spectra were generated using conditions similar to those described previously.<sup>25,26</sup> All NMR experiments were performed at 283 K using a Bruker Avance 700 MHz spectrometer equipped with a 5 mm cryoprobe with  $z$  gradients. NMR buffers contained 10 mM sodium phosphate (pH 7.7), 250 mM KCl, 0.1 mM Na<sub>2</sub>EDTA, and 5 mM MgCl<sub>2</sub>. Samples (400  $\mu$ L) contained 5  $\mu$ M human topoisomerase II $\alpha$  and 500  $\mu$ M etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol and were maintained at 4 °C until data were collected. STD <sup>1</sup>H NMR experiments employed a pulse scheme similar to that reported by Mayer and Meyer.<sup>34</sup> A 2 s saturation pulse was used for the saturation, with on- and

off-resonance irradiation frequencies of 0.5 and –71 ppm, respectively. The water signal was suppressed using excitation sculpting with gradients. For each experiment (on- and off-resonance irradiation), 256 scans were collected with a 2 s recycle time. Difference spectra were prepared by subtraction of the on-resonance spectrum from the off-resonance spectrum. Signals resulting in the difference spectrum represent the NOE difference signals generated by the transfer of irradiation energy from the enzyme to the bound ligand. Ligand protons in the spatial proximity of the enzyme displayed larger NOE signals. Mapping of the NOE signals with their proton assignments on the ligand revealed the ligand-binding epitope to human topoisomerase II $\alpha$ . Spectra were processed using Bruker Topsin.

**Cleavage Site Utilization in Linear Plasmid DNA.** DNA cleavage sites were mapped using a modification<sup>35</sup> of the procedure of O'Reilly and Kreuzer.<sup>36</sup> The pBR322 DNA substrate was linearized by treatment with *Hind*III. Terminal 5'-phosphates were removed by treatment with calf intestinal alkaline phosphatase and replaced with [<sup>32</sup>P]phosphate using T4 polynucleotide kinase and [ $\gamma$ -<sup>32</sup>P]ATP. The DNA was treated with *Eco*RI, and the 4332 bp singly end-labeled fragment was purified from the small *Eco*RI–*Hind*III fragment by passage through a CHROMA SPIN+TE-100 column (Clontech). Reaction mixtures contained 0.7 nM labeled pBR322 DNA and 90 nM human topoisomerase II $\alpha$  in 20  $\mu$ L of DNA cleavage buffer supplemented with 0.5 mM ATP in the absence of drug or in the presence of 10  $\mu$ M etoposide, 25  $\mu$ M DEPT, or 250  $\mu$ M retroetoposide, retroDEPT, or D-ring diol. Reaction mixtures were incubated for 6 min at 37 °C, and enzyme–DNA cleavage complexes were trapped by the addition of 2  $\mu$ L of 5% SDS followed by 2  $\mu$ L of 250 mM EDTA (pH 8.0). Proteinase K (2  $\mu$ L of a 0.8 mg/mL solution) was added, and samples were incubated for 30 min at 45 °C to digest the enzyme. DNA products were precipitated with ethanol and resuspended in 6  $\mu$ L of 40% formamide, 10 mM NaOH, 0.02% xylene cyanol FF, and 0.02% bromophenol blue. Samples were subjected to electrophoresis in denaturing 6% polyacrylamide sequencing gels. Gels were dried in vacuo, and DNA cleavage products were visualized with Bio-Rad Molecular Imager FX.

**Cleavage Site Utilization in Oligonucleotide Substrates.** A 47 bp oligonucleotide corresponding to residues 80–126 of pBR322 and its complement were employed to compare the DNA cleavage site specificity of etoposide to that of retroetoposide.<sup>37</sup> Oligonucleotide substrates were prepared on an Applied Biosystems DNA synthesizer. The sequences of the top and bottom strands were 5'-CCGTGTATGAAATCTAACAATX↓CGCTCATCGTCATCCTCGGCACCGT-3' and 5'-ACGGTGCCGAGGATGACGATG↓AGCGZATTGTTAGATTTTCATACACGG-3', respectively. This substrate contains a single strong cleavage site for topoisomerase II that has been well characterized.<sup>38–40</sup> Points of scission are denoted by arrows. Oligonucleotides were prepared that contained a G (found in the wild-type sequence), C, A, or T at the –1 position on the top strand (denoted by the bold X). Complementary bottom strand oligonucleotides contained a C, G, T, or A, respectively, at the position denoted by the bold Z. Single-stranded oligonucleotides were labeled at their 5'-termini using T4 polynucleotide kinase (New England Biolabs) and [ $\gamma$ -<sup>32</sup>P]ATP ( $\sim 6000$  Ci/mmol, Perkin-Elmer LAS). Following labeling and gel purification, complementary oligonucleotides were annealed by incubation at 70 °C for 10 min and cooling to 25 °C.






**Figure 2.** Effects of etoposide derivatives on DNA cleavage mediated by human topoisomerase II $\alpha$ . Levels of double-stranded DNA cleavage were expressed as the fold-enhancement vs those of reactions that were conducted in the absence of drug. Assay mixtures contained 0–200  $\mu$ M etoposide (●), DEPT (■), retroetoposide (rEtop, ○), retroDEPT (rDEPT, □), or D-ring diol (Δ). Error bars represent the standard deviation of three independent experiments.

DNA cleavage by human topoisomerase II $\alpha$  was assessed as described previously.<sup>28</sup> Reaction mixtures contained 220 nM human topoisomerase II $\alpha$  and 100 nM double-stranded oligonucleotide in 20  $\mu$ L of cleavage buffer containing 0–500  $\mu$ M etoposide or retroetoposide. Reaction mixtures were incubated for 10 min at 37 °C. DNA cleavage products were trapped by the addition of 2  $\mu$ L of 10% SDS, followed by 1  $\mu$ L of 375 mM EDTA (pH 8.0). Samples were digested with proteinase K, precipitated with ethanol, and resolved by electrophoresis in 7 M urea–14% polyacrylamide gels in 100 mM Tris-borate (pH 8.3) and 2 mM EDTA. DNA cleavage products were visualized and quantified on Bio-Rad Molecular Imager FX.

## RESULTS AND DISCUSSION

Interactions between topoisomerase II and substituents on the A-ring, E-ring, and C4 position of etoposide in the binary enzyme–drug complex (identified by STD <sup>1</sup>H NMR spectroscopy) predict the ability of etoposide to stabilize the covalent topoisomerase II–DNA cleavage complex.<sup>25,26</sup> However, retroetoposide and retroDEPT display reduced cytotoxicity (~8- and 32-fold, respectively, compared to that of etoposide) against murine leukemia L1210<sup>29</sup> despite the fact that NMR studies indicate that none of the protons on the D-ring of etoposide (i.e., the C2, C3, and C11 protons) contact human topoisomerase II $\alpha$  in the binary complex.<sup>25,26</sup> Although differences in drug cytotoxicity may reflect physiological attributes such as uptake or efflux, etc., this finding suggests that alterations in the D-ring of etoposide may affect drug activity toward topoisomerase II $\alpha$  in the ternary enzyme–drug–DNA complex.

**Activity of Etoposide D-Ring Derivatives against Human Topoisomerase II $\alpha$ .** To address the role of the D-ring in etoposide function, we compared the effects of retroetoposide, DEPT, retroDEPT, and the D-ring diol (see Figure 1 for structures) on DNA cleavage mediated by human topoisomerase II $\alpha$  to that of etoposide (Figure 2). As reported previously,<sup>26</sup> the activity of DEPT was ~80–90% of that of the parent compound.



**Figure 3.** DNA ligation was examined (left) in the absence of compound (no drug, ▲) or in the presence of 100  $\mu$ M etoposide (●), DEPT (■), retroetoposide (rEtop, ○), retroDEPT (rDEPT, □), or D-ring diol (Δ). Comparison (right) of DNA cleavage (black bars, 100  $\mu$ M drug) and ligation (white bars, 30 s) mediated by human topoisomerase II $\alpha$  in the presence of etoposide (E), DEPT (D), retroetoposide (rE), retroDEPT (rD), or D-ring diol (DRD). Error bars represent the standard deviation of three independent experiments.


In contrast, the ability of retroetoposide, retroDEPT, and the D-ring diol to stimulate enzyme-mediated DNA cleavage was decreased substantially. Levels of DNA scission observed in the presence of retroetoposide were ~2–3-fold lower than that seen with etoposide. The activity of retroDEPT was similarly reduced compared to that of DEPT and was lower than that of retroetoposide. Thus, the effects of the two changes in etoposide to generate retroDEPT (i.e., the loss of the C4 glycoside and the transposition of the C13 ketone to the C11 position) appear to be additive. Finally, the D-ring diol displayed no ability to stimulate DNA cleavage mediated by topoisomerase II $\alpha$ .

The results described above suggest that the decreased cytotoxicities of retroetoposide and retroDEPT are due, at least in part, to a decreased activity against topoisomerase II. Together with the findings for the D-ring diol, DNA cleavage results provide strong evidence that substituents on the D-ring of etoposide can profoundly affect the ability of the drug to act as a topoisomerase II poison.

It has been suggested that the diminished cellular activity of retroetoposide results from a deleterious interaction between the C4 glycoside and the C11 carbonyl group.<sup>29</sup> However, because the decreased activity of retroDEPT compared to DEPT was similar to that for retroetoposide compared to etoposide, this explanation seems unlikely.

Etoposide increases levels of cleavage complexes by inhibiting the ability of topoisomerase II to ligate DNA.<sup>41,42</sup> Therefore, the effects of the D-ring derivatives on DNA ligation mediated by topoisomerase II $\alpha$  were determined. As seen in Figure 3 (left panel), all of the compounds displayed reduced activity compared to that of etoposide, with the order being the same as that seen in DNA cleavage assays (etoposide > DEPT > retroetoposide > retroDEPT >> D-ring diol). Moreover, there was a strong correlation between the ability of the drugs to inhibit ligation and increased levels of DNA cleavage (right panel). These results indicate that the derivatives increase levels of topoisomerase II-mediated strand breaks by the same mechanism used by the parent compound (i.e., inhibition of DNA ligation).

As discussed above, retroetoposide and retroDEPT are cytotoxic to leukemia cells but are less potent than etoposide.<sup>29</sup>




**Figure 4.** Levels of topoisomerase II $\alpha$ –DNA cleavage complexes formed in human CEM leukemia cells that were treated with etoposide derivatives. DNA samples (10  $\mu$ g) from cultures treated with no drug (ND) or 25  $\mu$ M etoposide (E), DEPT (D), retroetoposide (rE), retroDEPT (rD), or D-ring diol (DRD) for 1 h were blotted onto a nitrocellulose membrane and probed with a polyclonal antibody directed against human topoisomerase II. Error bars represent the standard deviation of three independent experiments. A representative blot is shown at the top.

Therefore, to determine whether the reduced cytotoxicity of D-ring derivatives correlates with a decreased activity against topoisomerase II $\alpha$ , we assessed the ability of DEPT, retroetoposide, retroDEPT, and the D-ring diol to induce DNA cleavage by the type II enzyme in cultured human CEM leukemia cells. As seen in Figure 4, drug activity correlated with results of the in vitro DNA cleavage assays: DEPT, retroetoposide, and retroDEPT (in that order) induced reduced cellular levels of cleavage complexes compared to etoposide, and the D-ring diol displayed no activity. These findings strongly suggest that the cytotoxicity of retroetoposide and retroDEPT reflects the activity of the drug against topoisomerase II $\alpha$ .

**Interactions of Etoposide D-Ring Derivatives with Human Topoisomerase II $\alpha$ .** Although the C2, C3, and C11 protons associated with the D-ring of etoposide do not appear to interact with topoisomerase II $\alpha$  in the binary complex,<sup>25,26</sup> alterations in the D-ring profoundly affect the ability of the drug to poison topoisomerase II $\alpha$  in vitro and in cultured human cells (Figures 2 and 4). This dichotomy suggests one of two things: either alterations in the D-ring affect contacts between etoposide and the enzyme in the binary complex, or this portion of etoposide has critical interactions in the ternary complex that are not reflected in the absence of DNA. To address these possibilities, we identified interactions between topoisomerase II $\alpha$  and retroetoposide, retroDEPT, and the D-ring diol by STD  $^1$ H NMR spectroscopy.

Off-resonance and difference spectra for samples containing topoisomerase II $\alpha$  and retroetoposide, retroDEPT, and the D-ring diol are shown in Figure 5. Resonances for all visible protons for these drugs, as well as etoposide and DEPT, are listed in Table 1.

With the exception of one additional contact with the enzyme (the C4 proton of the C-ring), the substituents on retroetoposide and retroDEPT that interact with human topoisomerase II $\alpha$  in the binary complex were the same as those previously described for etoposide and DEPT.<sup>25,26</sup> However, the nuclear Overhauser enhancement (NOE) signals seen for the E-ring protons of both drugs were substantially broader than those found with etoposide in the binary complex. This finding suggests that movement of the C13 carbonyl group to the C11 position may alter the



**Figure 5.** Interaction of retroetoposide (top), retroDEPT (middle), and D-ring diol (bottom) with human topoisomerase II $\alpha$  as determined by STD  $^1$ H NMR spectroscopy. Difference and reference (off-resonance) spectra are shown for each drug. Spectra are representative of at least two independent experiments.


conformation around the E-ring of etoposide and affect interactions between this portion of the drug and the enzyme.

In contrast to retroetoposide and retroDEPT, the substituents on the D-ring diol that contact topoisomerase II $\alpha$  in the binary

**Table 1. Drug Substituents That Interact with Human Topoisomerase II $\alpha$  in the Binary Enzyme–Drug Complex As Determined by STD  $^1\text{H}$  NMR Spectroscopy<sup>a</sup>**

etoposide		retroetoposide		DEPT		retroDEPT		D-ring diol	
substituent	resonance	substituent	resonance	substituent	resonance	substituent	resonance	substituent	resonance
1	4.39	1	4.31	1	4.38	1	4.26	1	4.28
2	3.33	2	3.21	2	3.10	2	3.21	2	2.50
3	2.83	3	2.88	3	2.81	3	2.76	3	2.5
4	4.82	<b>4</b>	<b>5.07</b>	4	4.77	<b>4</b>	<b>4.84</b>	4	4.59
<b>5</b>	<b>6.70</b>	<b>5</b>	<b>6.75</b>	<b>5</b>	<b>6.70</b>	<b>5</b>	<b>6.70</b>	<b>5</b>	<b>6.53</b>
<b>8</b>	<b>6.32</b>	<b>8</b>	<b>6.33</b>	<b>8</b>	<b>6.28</b>	<b>8</b>	<b>6.30</b>	<b>8</b>	<b>6.32</b>
11R, 11S	4.15, 4.20	13R, 13S	3.34, 4.34	11R, 11S	4.09, 4.25	13R, 13S	3.45, 4.32		
<b>15R, 15S</b>	<b>5.70</b>	<b>15R, 15S</b>	<b>5.73</b>	<b>15R, 15S</b>	<b>5.67</b>	<b>15R, 15S</b>	<b>5.68</b>	<b>15R, 15S</b>	<b>5.66</b>
<b>2', 6'</b>	<b>6.18</b>	<b>2', 6'</b>	<b>6.15<sup>b</sup></b>	<b>2', 6'</b>	<b>6.11</b>	<b>2', 6'</b>	<b>6.07<sup>b</sup></b>	<b>2', 6'</b>	<b>6.26</b>
<b>3'-OCH<sub>3</sub>, 5'-OCH<sub>3</sub></b>	<b>3.49</b>	<b>3'-OCH<sub>3</sub>, 5'-OCH<sub>3</sub></b>	<b>3.49<sup>b</sup></b>	<b>3'-OCH<sub>3</sub>, 5'-OCH<sub>3</sub></b>	<b>3.45</b>	<b>3'-OCH<sub>3</sub>, 5'-OCH<sub>3</sub></b>	<b>3.59<sup>b</sup></b>	<b>3'-OCH<sub>3</sub>, 5'-OCH<sub>3</sub></b>	<b>3.54</b>
1''	4.43	3''	4.44					11-CH <sub>2</sub>	3.44, 3.65
2''	3.07	5''	3.00					13-CH <sub>2</sub>	3.35, 3.53
3''	3.33	6''	3.37						
4''	3.17	7''	3.17						
5''	3.24	9'', 12''	3.08						
6'', 6''	3.42, 4.01	10'', 11''	3.40, 3.97						
7''	4.70	14'', 16''	4.64						
-CH <sub>3</sub>	1.10	15''	1.10						

<sup>a</sup> Resonances that display nuclear Overhauser effects in STD  $^1\text{H}$  NMR spectroscopy experiments along with the substituent protons that they represent are indicated in bold and are underlined. <sup>b</sup> Resonances were substantially broadened.



**Figure 6.** Competition between the D-ring diol and etoposide in the ternary complex. Topoisomerase II $\alpha$ -mediated DNA cleavage in the presence of 50  $\mu\text{M}$  etoposide and increasing concentrations (up to 500  $\mu\text{M}$ ) of D-ring diol is shown as the fold-enhancement over that of etoposide alone. Error bars represent the standard deviation of three independent experiments.


complex were identical to those of etoposide and no broadening of the E-ring proton resonances were observed. This result indicates that the loss of the D-ring does not alter drug interactions in the binary complex and implies that the lack of DNA cleavage enhancement induced by this derivative results from a specific difference in drug interactions within the ternary complex. Therefore, a competition assay was conducted to address this possibility. As seen in Figure 6, the D-ring diol was unable to displace 50  $\mu\text{M}$  etoposide from the ternary topoisomerase II $\alpha$ –DNA cleavage

complex, even at concentrations that were 10-fold higher than that of the parent compound. Thus, despite the fact that the D-ring diol and etoposide display similar contacts with topoisomerase II $\alpha$  in the binary complex, their interactions in the ternary complex (at least with regard to strength) appear to differ. Because the difference between the binary and ternary complex is the presence of DNA, this finding suggests that the D-ring may have important interactions with the double helix in the covalent topoisomerase II $\alpha$ –drug–DNA cleavage complex.

**Effects of D-Ring Substitutions on the Specificity of Topoisomerase II $\alpha$ -Mediated DNA Cleavage.** A previous study demonstrated that removal of the C4 glycoside alters the specificity of etoposide-induced DNA cleavage by human topoisomerase II $\alpha$  (also shown in Figure 7).<sup>26</sup> Consequently, it was proposed that the sugar moiety of etoposide interacts with DNA in the cleavage complex. Because the etoposide D-ring does not appear to contact topoisomerase II $\alpha$  in the binary complex but modification of this group significantly diminishes drug activity, sites of cleavage were mapped to determine if the D-ring also has the potential to interact with the double helix in the cleavage complex.


As seen in Figure 7, there were substantial differences in the cleavage specificity and site utilization of topoisomerase II $\alpha$  in the presence of etoposide versus retroetoposide. Similar differences were seen upon comparison of cleavage maps generated in the presence of DEPT and retroDEPT. In addition, opening of the D-ring (D-ring diol) abolished all sites of drug-induced DNA cleavage. These results indicate that the specificity of etoposide-induced DNA cleavage is governed, at least in part, by the D-ring. Furthermore, the results are consistent with the hypothesis that the D-ring contacts DNA in the topoisomerase II $\alpha$  cleavage complex. Because movement of the C13 carbonyl to the C11 position appears to affect the conformation of the





**Figure 7.** DNA cleavage site specificity and utilization by human topoisomerase II $\alpha$  in the presence of etoposide derivatives. A singly end-labeled linear 4332 bp fragment of pBR322 was used as the cleavage substrate. An autoradiogram of a polyacrylamide gel is shown. DNA cleavage reaction mixtures contained topoisomerase II $\alpha$  with no drug (Topo), 10  $\mu$ M etoposide (Etop), 250  $\mu$ M retroetoposide (rEtop), 25  $\mu$ M DEPT (DEPT), 250  $\mu$ M retroDEPT (rDEPT), or 250  $\mu$ M D-ring diol (DRD). A DNA control (DNA) also is shown. Data are representative of four independent experiments.

etoposide E-ring, an alternative hypothesis is that D-ring alterations affect cleavage specificity by indirectly changing protein–drug contacts. However, two findings argue against this latter interpretation. First, the D-ring diol displays no ability to induce topoisomerase II $\alpha$ -mediated DNA cleavage, despite the fact that the protein–drug contacts in the binary complex are the same as those seen with etoposide. Second, a previous study found that derivatization of the etoposide E-ring significantly diminishes



**Figure 8.** Oligonucleotide sequence specificity of etoposide (●) vs retroetoposide (○). Drug titrations were performed using an oligonucleotide substrate that contained a strong cleavage site for human topoisomerase II $\alpha$ . The oligonucleotide was synthesized with either a C, A, T, or G at position  $-1$  relative to the scissile bond. The inset in the bottom right panel compares DNA cleavage levels induced by 250  $\mu$ M etoposide (black bars) or retroetoposide (white bars) relative to cleavage of the oligonucleotide containing a C at position  $-1$ , which was set at 1 for both drugs. Error bars represent the standard deviation of three independent experiments.


levels of drug-induced DNA cleavage but has no effect on the site specificity of human topoisomerase II $\alpha$ .<sup>25</sup>

To further examine the effects of D-ring derivatization on the cleavage specificity of the type II enzyme, we compared the ability of etoposide and retroetoposide to induce topoisomerase II $\alpha$ -mediated DNA cleavage of an oligonucleotide substrate. Etoposide displays specificity for the  $-1$  base relative to the scissile bond and generally prefers to cleave substrates with a C at this position.<sup>43,44</sup> With the oligonucleotide used for cleavage experiments, etoposide preferentially induced cleavage when the substrate contained a C or A at position  $-1$  (Figure 8). Scission levels dropped  $\sim 2$ -fold when a T or G was present at this position.

Compared to etoposide, retroetoposide displays a decreased specificity for a C or A at position  $-1$  (Figure 8). In fact, levels of topoisomerase II $\alpha$ -mediated DNA scission with the  $-1$  G substrate were comparable to those seen in the presence of C or A. This finding confirms that changes in the D-ring of etoposide alter the DNA cleavage specificity of the drug.

**Conclusions.** Although etoposide is in its fourth decade of clinical use, relationships between drug activity and interactions within the binary topoisomerase II–drug complex and the ternary topoisomerase II–drug–DNA complex have been addressed only recently. On the basis of the results of STD  $^1\text{H}$  NMR spectroscopy and enzyme–drug binding in the binary complex, as well as drug competition and DNA cleavage in the ternary complex, a model has emerged (Figure 9). In this model, the binding of etoposide to human topoisomerase II $\alpha$  is driven by interactions with the A-ring and B-ring and potentially by stacking interactions with the E-ring.<sup>25,26</sup> The E-ring methoxy groups and the 4'-OH moiety are important for drug function but do not contribute substantially to enzyme–drug binding or DNA cleavage specificity.<sup>25,26</sup>





**Figure 9.** Summary of etoposide substituents that interact with human topoisomerase II $\alpha$ . Protons that interact with the enzyme (as determined by STD  $^1\text{H}$  NMR spectroscopy) are colored red.<sup>25,26</sup> Interactions between hydroxyl protons and the enzyme were obscured by the water peak and could not be visualized. The blue region on etoposide, including portions of the A-, B-, and E-rings, is proposed to interact with topoisomerase II $\alpha$  in the binary drug–enzyme complex. E-Ring substituents highlighted with yellow boxes are important for drug function and interact with the enzyme but do not appear to contribute significantly to binding.<sup>25,26</sup> We propose that interactions between etoposide and DNA in the ternary complex (shaded in gray) are driven primarily by the D-ring, with additional contributions from the C4 sugar.

Neither the C4 glycoside nor the D-ring of etoposide contacts the enzyme in the binary complex.<sup>25,26</sup> While removal of the sugar has little effect on drug activity, it subtly alters the specificity of DNA cleavage. In contrast, D-ring modifications profoundly affect the ability of etoposide to induce DNA scission and alter the cleavage specificity of topoisomerase II $\alpha$ . Taken together, we propose that interactions between etoposide and DNA in the ternary complex are driven primarily by the D-ring, with additional contributions from the C4 sugar. This hypothesis is supported by recent studies with F14512, an etoposide derivative that replaces the C4 glycoside with a spermine moiety.<sup>45–47</sup> The presence of the spermine enhances DNA interactions and increases the potency of the drug against human type II topoisomerases.<sup>45–47</sup> Thus, by targeting the C4 moiety and the D-ring, it may be possible to develop novel etoposide derivatives with increased activity and/or altered cleavage specificity.

## AUTHOR INFORMATION

### Corresponding Author

\*Correspondence regarding NMR should be addressed to D.E.G. Telephone: (205) 975-5381. Fax: (205) 975-2543. E-mail: dgraves@uab.edu. Correspondence regarding DNA topoisomerase II should be addressed to N.O. Telephone: (615) 322-4338. Fax: (615) 343-1166. E-mail: neil.osheroff@vanderbilt.edu.

### Present Addresses

- ▼CNRS UMR6001, University of Nice, Nice, France.
- CNRS-Pierre Fabre USR3388, Toulouse, France.

### Funding Sources

This work was supported by National Institutes of Health Grant GM33944 (N.O.), Department of Defense Grant DOD/CDMRP-BCRP BC095831P1 (D.E.G.), and Ligue Nationale Contre le Cancer and ACI 'Molécules et Cibles Thérapeutiques' du Ministère de la Recherche (P.B.A.).

## ACKNOWLEDGMENT

We are grateful to Dr. Amanda C. Gentry, Adam C. Ketron, and Katie J. Aldred for critical reading of the manuscript.

## ABBREVIATIONS

DEPT, 4'-demethyl epipodophyllotoxin; retroetoposide, 11-oxo-13-deoxy-etoposide; retroDEPT, 11-oxo-13-deoxy-4'-demethyl epipodophyllotoxin; D-ring diol, 11,13-O,4'-demethyl epipodophyllotoxin; STD, saturation transfer difference; NOE, nuclear Overhauser enhancement.

## REFERENCES

- (1) Hande, K. R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. *Eur. J. Cancer* 34, 1514–1521.
- (2) Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. *Biochim. Biophys. Acta* 1400, 173–184.
- (3) Holden, J. A. (2001) DNA topoisomerases as anticancer drug targets: From the laboratory to the clinic. *Curr. Med. Chem.: Anti-Cancer Agents* 1, 1–25.
- (4) Baldwin, E. L., and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer. *Curr. Med. Chem.: Anti-Cancer Agents* 5, 363–372.
- (5) Nitiss, J. L., Liu, Y. X., and Hsiung, Y. (1993) A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: A genetic system for determining the targets of topoisomerase II inhibitors. *Cancer Res.* 53, 89–93.
- (6) Pommier, Y., and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions. *Curr. Med. Chem.: Anti-Cancer Agents* 5, 421–429.
- (7) McClendon, A. K., and Osheroff, N. (2007) DNA topoisomerase II, genotoxicity and cancer. *Mutat. Res.* 623, 83–97.
- (8) Dewese, J. E., and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing. *Nucleic Acids Res.* 37, 738–748.
- (9) Nitiss, J. L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy. *Nat. Rev. Cancer* 9, 338–350.
- (10) Baguley, B. C., and Ferguson, L. R. (1998) Mutagenic properties of topoisomerase-targeted drugs. *Biochim. Biophys. Acta* 1400, 213–222.
- (11) Kaufmann, S. H. (1998) Cell death induced by topoisomerase-targeted drugs: More questions than answers. *Biochim. Biophys. Acta* 1400, 195–211.
- (12) Sordet, O., Khan, Q. A., Kohn, K. W., and Pommier, Y. (2003) Apoptosis induced by topoisomerase inhibitors. *Curr. Med. Chem.: Anti-Cancer Agents* 3, 271–290.
- (13) Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., and Crooke, S. T. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. *J. Biol. Chem.* 262, 16739–16747.
- (14) Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. *Biochemistry* 28, 8154–8160.
- (15) Champoux, J. J. (2001) DNA topoisomerases: Structure, function, and mechanism. *Annu. Rev. Biochem.* 70, 369–413.
- (16) Velez-Cruz, R., and Osheroff, N. (2004) DNA topoisomerases: Type II. In *Encyclopedia of Biological Chemistry* (Lennarz, W., and Lane, M. D., Eds.) Vol. I, pp 806–811, Elsevier Science Inc., San Diego.
- (17) Sehested, M., Holm, B., and Jensen, P. B. (1996) Dexrazoxane for protection against cardiotoxic effects of anthracyclines. *J. Clin. Oncol.* 14, 2884.
- (18) Azarova, A. M., Lyu, Y. L., Lin, C. P., Tsai, Y. C., Lau, J. Y., Wang, J. C., and Liu, L. F. (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. *Proc. Natl. Acad. Sci. U.S.A.* 104, 11014–11019.

- (19) Lyu, Y. L., Kerrigan, J. E., Lin, C. P., Azarova, A. M., Tsai, Y. C., Ban, Y., and Liu, L. F. (2007) Topoisomerase II $\beta$  mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Cancer Res.* 67, 8839–8846.
- (20) Keith, W. N., Tan, K. B., and Brown, R. (1992) Amplification of the topoisomerase II $\alpha$  gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II $\alpha$  and  $\beta$  loci in normal tissue. *Genes, Chromosomes Cancer* 4, 169–175.
- (21) Keith, W. N., Douglas, F., Wishart, G. C., McCallum, H. M., George, W. D., Kaye, S. B., and Brown, R. (1993) Co-amplification of erbB2, topoisomerase II $\alpha$  and retinoic acid receptor  $\alpha$  genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. *Eur. J. Cancer* 10, 1469–1475.
- (22) Skotheim, R. I., Kallioniemi, A., Bjerkhagen, B., Mertens, F., Brekke, H. R., Monni, O., Mousses, S., Mandahl, N., Soeter, G., Nesland, J. M., Smeland, S., Kallioniemi, O. P., and Lothe, R. A. (2003) Topoisomerase II $\alpha$  is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. *J. Clin. Oncol.* 21, 4586–4591.
- (23) Burden, D. A., Kingma, P. S., Froelich-Ammon, S. J., Bjornsti, M. A., Patchan, M. W., Thompson, R. B., and Osheroff, N. (1996) Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. *J. Biol. Chem.* 271, 29238–29244.
- (24) Kingma, P. S., Burden, D. A., and Osheroff, N. (1999) Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance. *Biochemistry* 38, 3457–3461.
- (25) Wilstermann, A. M., Bender, R. P., Godfrey, M., Choi, S., Anklin, C., Berkowitz, D. B., Osheroff, N., and Graves, D. E. (2007) Topoisomerase II-drug interaction domains: Identification of substituents on etoposide that interact with the enzyme. *Biochemistry* 46, 8217–8225.
- (26) Bender, R. P., Jablonsky, M. J., Shadid, M., Romaine, I., Dunlap, N., Anklin, C., Graves, D. E., and Osheroff, N. (2008) Substituents on etoposide that interact with human topoisomerase II $\alpha$  in the binary enzyme-drug complex: Contributions to etoposide binding and activity. *Biochemistry* 47, 4501–4509.
- (27) Worland, S. T., and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* 264, 4412–4416.
- (28) Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase II $\alpha$  and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. *Biochemistry* 36, 5934–5939.
- (29) Meresse, P., Magiatis, P., Bertounesque, E., and Monneret, C. (2003) Synthesis and antiproliferative activity of retroetoposide. *Bioorg. Med. Chem. Lett.* 13, 4107–4109.
- (30) Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase II $\alpha$  by blocking DNA cleavage. *J. Biol. Chem.* 273, 17643–17650.
- (31) Byl, J. A., Fortune, J. M., Burden, D. A., Nitiss, J. L., Utsugi, T., Yamada, Y., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: Primary cellular target and DNA cleavage enhancement. *Biochemistry* 38, 15573–15579.
- (32) Subramanian, D., Kraut, E., Staubus, A., Young, D. C., and Muller, M. T. (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan. *Cancer Res.* 55, 2097–2103.
- (33) Byl, J. A., Cline, S. D., Utsugi, T., Kobunai, T., Yamada, Y., and Osheroff, N. (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action. *Biochemistry* 40, 712–718.
- (34) Mayer, M., and Meyer, B. (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. *J. Am. Chem. Soc.* 123, 6108–6117.
- (35) Baldwin, E. L., Byl, J. A., and Osheroff, N. (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase II $\alpha$  in vitro and in cultured cells. *Biochemistry* 43, 728–735.
- (36) O'Reilly, E. K., and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. *Biochemistry* 41, 7989–7997.
- (37) Bromberg, K. D., Burgin, A. B., and Osheroff, N. (2003) A two-drug model for etoposide action against human topoisomerase II $\alpha$ . *J. Biol. Chem.* 278, 7406–7412.
- (38) Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from *Drosophila melanogaster*. *J. Biol. Chem.* 258, 8421–8428.
- (39) Corbett, A. H., Zechiedrich, E. L., and Osheroff, N. (1992) A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage. *J. Biol. Chem.* 267, 683–686.
- (40) Kingma, P. S., and Osheroff, N. (1997) Apurinic sites are position-specific topoisomerase II-poisons. *J. Biol. Chem.* 272, 1148–1155.
- (41) Osheroff, N. (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide. *Biochemistry* 28, 6157–6160.
- (42) Robinson, M. J., and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. *Biochemistry* 30, 1807–1813.
- (43) Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. *Nucleic Acids Res.* 19, 5973–5980.
- (44) Capranico, G., and Binaschi, M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. *Biochim. Biophys. Acta* 1400, 185–194.
- (45) Barret, J. M., Kruczynski, A., Vispe, S., Annereau, J. P., Brel, V., Guminski, Y., Delcros, J. G., Lansiaux, A., Guilbaud, N., Imbert, T., and Bailly, C. (2008) F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. *Cancer Res.* 68, 9845–9853.
- (46) Kruczynski, A., Vandenberghe, I., Pillon, A., Pesnel, S., Goetsch, L., Barret, J. M., Guminski, Y., Le Pape, A., Imbert, T., Bailly, C., and Guilbaud, N. (2011) Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. *Invest. New Drugs* 29, 9–21.
- (47) Gentry, A. C., Pitts, S. L., Jablonsky, M. J., Bailly, C., Graves, D. E., and Osheroff, N. (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. *Biochemistry* 50, 3240–3249.